Patient and Healthcare Provider Resource

Patient and Healthcare Providers Resource, Patient + Healthcare Providers Resource, the Patient and Healthcare Providers Resource







Enasidenib (Idhifa) is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 gene, determined by an FDA-approved IDH2 companion diagnostic test. It is an inhibitor of IDH2.

Our Medication Sheet

This sheet is coming soon. check back later to download it as an Adobe PDF.


Our Foundation Sponsors

Our Sustaining Sponsors